Suppr超能文献

[应用双重免疫细胞化学方法评估各种淋巴增殖性疾病中淋巴细胞的增殖及谱系]

[Evaluation of the proliferation and line of lymphoid cells in various lymphoproliferative diseases using a double immunocytochemical method].

作者信息

Malashenko O S, Samoĭlova R S, Bulycheva T I

出版信息

Gematol Transfuziol. 1994 May-Jun;39(3):3-7.

PMID:8076790
Abstract

The increased range of the diagnostic criteria and the introduction of the classification scheme "Practical Formulation of Non-Hodgkin's Lymphomas for Clinical Application" made the authors to study proliferative potential of lymphoid cells with identification of the cell line affiliation. The investigation was carried out with the use of the double immunocytochemical test employing anti-nuclear (Ki-67) and line-specific monoclonal antibodies on peripheral blood lymphocytes, those of lymph nodes and bone marrow obtained from 40 patients with lymphoproliferative diseases and on the cells of lymphoblastoid line 501. The disease variant was classified according to the WHO criteria. The highest (> 60%) proliferative activity of lymphoid cells was found in the bone marrow in acute non-T non-B lymphoblast leukemia and in lymph node in T-cell and non-T non-B-cell lymphoblast lymphosarcoma. A broad range in the number of proliferative cells existed among B-cell lymphosarcomas of lymphoblast (12-73%) and prolymphocytic (0-91%) variants. Together with heterogeneous immunological phenotype, this reflects a wide spectrum of various nosological entities recognized by the WHO classification as lymphoblast and prolymphocytic variants of lymphosarcoma, says about the defects of the above classification. Extremely low (< 1%) percent of proliferative cells was observed in B-cell chronic lymphoid leukemia and hairy-cell leukemia. These differences in tumor cell proliferative potential in different lymphoproliferative diseases agree with the views on maturation and differentiation of lymphoid cells. The data obtained by the authors support the necessity of correcting routine histological data by immunological characteristics of pathological lymphoid cells, primarily, by introduction of data on cell proliferative activity.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

诊断标准范围的扩大以及“非霍奇金淋巴瘤临床应用实用分类方案”的引入,促使作者研究淋巴细胞的增殖潜能并确定细胞系归属。研究采用双免疫细胞化学检测,使用抗核(Ki-67)抗体和谱系特异性单克隆抗体,对40例淋巴增殖性疾病患者的外周血淋巴细胞、淋巴结细胞和骨髓细胞以及淋巴母细胞系501的细胞进行检测。疾病变异根据世界卫生组织(WHO)标准分类。在急性非T非B淋巴母细胞白血病的骨髓以及T细胞和非T非B细胞淋巴母细胞淋巴瘤的淋巴结中,发现淋巴细胞的增殖活性最高(>60%)。在淋巴母细胞型(12 - 73%)和原淋巴细胞型(0 - 91%)变异的B细胞淋巴瘤中,增殖细胞数量范围较广。连同异质性免疫表型一起,这反映了WHO分类中被认可为淋巴瘤的淋巴母细胞型和原淋巴细胞型变异的各种疾病实体范围广泛,也说明了上述分类存在缺陷。在B细胞慢性淋巴细胞白血病和毛细胞白血病中,观察到增殖细胞的百分比极低(<1%)。不同淋巴增殖性疾病中肿瘤细胞增殖潜能的这些差异与关于淋巴细胞成熟和分化的观点一致。作者获得的数据支持有必要根据病理性淋巴细胞的免疫特征,主要是通过引入细胞增殖活性数据来校正常规组织学数据。(摘要截短为250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验